# Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

> **NCT04189848** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 104 (actual)

## Conditions studied

- Healthy Volunteers
- Diabetes Mellitus, Type 2
- Overweight
- Obesity

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Dulaglutide

## Key facts

- **NCT ID:** NCT04189848
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-03
- **Primary completion:** 2020-01-29
- **Final completion:** 2020-02-27
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2022-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04189848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04189848, "Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04189848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*